Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins - PubMed (original) (raw)

Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins

Meral Ekim et al. Pak J Med Sci. 2015 Mar-Apr.

Abstract

Objectives: Hyperhomocysteinemia has been considered as a potential risk factor for deep venous thrombosis (DVT) but it is still controversy. We aimed to evaluate the prevalence of hyperhomocysteinemia in patients with DVT. Our second objective was to document the prevalence of folate, Vitamin B6, and Vitamin B12 level in this patient population.

Methods: Sixty patients with DVT aged from 23 to 84 years, were assessed regarding demographic characteristics, serum levels of homocysteine, folate, vitamin B12, and vitamin B6. The diagnosis of DVT was based upon Wells scoring system and serum D-dimer level and confirmed by deep venous Doppler ultrasonography of the lower limbs.

Results: Mean serum homocysteine levels were found significantly higher in patients over the age of 40 years (10.81±4.26 µmol/L vs 9.13±3.23 µmol/L). Of all the patients, 9 patients had homocysteine level above the 15µmol/L, 26 had folic acid level below 3 ng/ml, one had vitamin B12 level below 150 pmol/L, and two had vitamin B6 level below 30 nmol/L. In the hyperhomocysteinemic group, five patients had low folic acid level, one had low vitamin B12 level, and two had low vitamin B6 level.

Conclusions: Hyperhomocysteinemia, in women older than 40 years, may be a risk factor for DVT. Folic acid deficiency may also influence serum homocysteine concentrations. Folate therapy may be offered to the patients with DVT. However further studies are required to clarify the underlying molecular mechanisms.

Keywords: B Group Vitamin; Deep Venous Trombosis; Hyperhomocysteinemia.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflict of interests: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Similar articles

Cited by

References

    1. Reitsma PH, Versteeg HH, Middeldorp S. Mechanisthic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012;32:563–568. DOI:10.1161/ATVBAHA.111.242818. - PubMed
    1. Ravari H, Zafarghandi MR, Alvandfar D, Saadat S. Serum homocysteine in deep venous thrombosis, peripheral atherosclerosis & healthy Iranians: A case-control study. Pak J Biol Sci. 2009;12(14):1019–1024. - PubMed
    1. Clarke R. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ. 1998;316:894–898. - PMC - PubMed
    1. Ducros V, Barro C, Yver J, Pernod G, Polack B, Carpentier P. Should plasma homocysteine be used as a biomarker of venous thromboembolism? A case-control study. Clin Appl Thromb Hemos. 2009;15:571–522. DOI:10.1177/1076029608322548. - PubMed
    1. Hainaut P, Jaumotte C, Verhelst D, Wallemacq P, Gala Jean-Lu, Lavenne E. Hyperhomocysteinemia & venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res. 2002;106:121–125. - PubMed

LinkOut - more resources